|
|
|
|
|
|
|
|
|
|
abstract:
Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival
Purpose
The
aim of this study was to evaluate whether body weight changes in
patients undergoing chemotherapy for epithelial ovarian cancer (EOC)
influence progression-free survival (PFS) and overall survival (OS).
Methods
An
analysis of 190 patients diagnosed with ovarian cancer after first-line
chemotherapy was conducted. Changes in body weight were assessed by
comparing measurements at baseline to those of the third and sixth
cycles of chemotherapy. PFS and OS were calculated with the Kaplan–Meier
method and multivariate Cox model.
Results
Significant
reduction in body weight in advanced EOC was observed with no changes
in early EOC. Significant differences in PFS were observed in advanced
EOC patients that lost more than 5 % of their body weight (6 months),
maintained weight (13 months), or gained more than 5 % of their body
weight (15 months). Similarly, significant differences in OS were noted
in advanced EOC at the following time points: 24.3, 42.4, and
66.2 months. No effect was reported for early EOC patients. The
multivariate Cox analysis showed significant body weight changes from
the first to the sixth chemotherapy cycle for PFS (HR = 0.97) and OS (HR = 0.94) as well as from the
first to the third chemotherapy cycle for OS (HR = 0.93).
Conclusions
Body
weight changes can be recognized as a prognostic factor for PFS and OS
in advanced EOC patients undergoing chemotherapy. Weight loss is
associated with poorer survival while weight gain improved outcomes.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.